Immunotherapy

Papers
(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Imaging of brain metastases treated with immune checkpoint inhibitors112
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study38
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma29
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma28
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia26
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study24
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study23
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy23
Disrupting neuro-immune feedback loops: novel targets to amplify cancer immunotherapy21
Postvaccination immune-mediated hepatitis: what do we really know?20
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-15820
MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers19
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis18
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas18
The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives18
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?18
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data18
Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report16
Nivolumab induced discolouration of the tongue: a case report16
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report16
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors16
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?15
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors15
Cancer Immunotherapy Via Stem Cell-Derived NK Cells15
Adherence, persistence and treatment switching in psoriasis14
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis14
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer14
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy14
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-2714
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review13
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma13
Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results13
Germinal center immune dynamics: challenges for effective vaccination in the elderly13
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins13
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report13
Immunotherapy expectations and knowledge in practice and clinical trials: a cross-sectional study12
Liquid biopsy for guiding breast cancer immunotherapy11
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics11
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges11
Immune Checkpoint Inhibitors in Cholangiocarcinoma10
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice10
Immune-Related Gigantomastia: A Case Study10
Deucravacitinib in Moderate-To-Severe Psoriasis10
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?10
Clinical optimization of bexmarilimab as a myeloid checkpoint therapy10
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma10
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management10
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations10
Effectiveness of COVID-19 Vaccines Against Omicron Variant10
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report10
Integrase inhibitors: current protagonists in antiretroviral therapy9
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?9
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib9
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis9
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer9
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer9
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature9
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis9
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens9
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report9
Conversion surgery after pembrolizumab for initially unresectable MSI-H small bowel adenocarcinoma: a case report and brief analysis9
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far9
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab9
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies9
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma9
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary9
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis8
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease8
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab8
Pembrolizumab in an HIV-infected patient with glioblastoma8
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs8
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma8
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients8
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China8
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)8
Abrocitinib for the Treatment of Atopic Dermatitis8
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis8
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes8
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?8
Immunotherapies for prevention and treatment of type 1 diabetes7
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer7
Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours7
Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival7
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy7
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review7
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database7
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events7
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma7
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy7
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study7
Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy7
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis7
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis7
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases6
Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease6
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study6
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates6
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature6
Sublingual immunotherapy suppresses Th2-type immune response in the allergic rhinitis mouse model by inhibiting the activation of the NFκB pathway6
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary6
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan6
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment6
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis6
Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions6
Allogeneic CAR-T cells for cancer immunotherapy6
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus6
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma6
Immunotherapy of endometrial cancer: a review of recent advances6
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy6
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis6
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer6
Oncolytic Viruses in Lung Cancer Treatment: A Review Article6
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?6
Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy6
Could senescent cells be the prescription for therapeutic cancer vaccines?6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review6
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy6
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis6
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review6
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations6
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy5
Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis5
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement5
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery5
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease5
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors5
Friendly fire? A case of inadvertent reactivation and progression of chronic lymphocytic leukemia following the treatment of cutaneous squamous cell carcinoma with Cemiplimab – case report5
Imaging-calculated splenic volume is associated with response in melanoma patients treated with immunotherapy5
Oncolytic viruses in brain cancer therapy: advances, challenges, and clinical trial outcomes5
Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents5
Overcoming Immune-Resistance in Laryngeal Cancer: A Case Report of the Abscopal Effect and Nivolumab Beyond Progression5
Cemiplimab-Induced Cytokine-Release Syndrome: Second Case Reported and Review of The Literature5
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study5
The potential of phytomedicines to optimize CAR-T cell therapy in cancer5
Tsunami of Immunotherapies in the Management of Esophageal Cancer5
Plain language summary of disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT5
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy5
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event5
Immune Checkpoint Inhibitors and Combinations with Other Agents in Cholangiocarcinoma5
Immunotherapy in Atopic Dermatitis5
Effect of Neoadjuvant Therapy on Tumor Tissue PD-L1 and VISTA Expression Levels in Non-Small-Cell Lung Cancer5
Bimekizumab for The Treatment of Psoriasis5
Beyond conventional therapies: immunotherapeutic strategies targeting HPV-associated cervical cancer5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review5
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study5
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management5
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives5
Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial5
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults5
Drug evaluation: mepolizumab in chronic obstructive pulmonary disease5
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis5
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?5
0.078155994415283